Standout Papers

Histone deacetylases and cancer: causes and therapies 1999 2026 2008 2017 1.5k
  1. Histone deacetylases and cancer: causes and therapies (2001)
    Paul A. Marks, Richard A. Rifkind et al. Nature reviews. Cancer
  2. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors (1999)
    Michael S. Finnin, Jill R. Donigian et al. Nature
  3. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug (2007)
    Paul A. Marks, Ronald Breslow Nature Biotechnology
  4. Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation (2000)
    Victoria M. Richon, Todd W. Sandhoff et al. Proceedings of the National Academy of Sciences
  5. Histone Deacetylase Inhibitors: Overview and Perspectives (2007)
    Milos Dokmanovic, Paul A. Marks et al. Molecular Cancer Research
  6. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases (1998)
    Victoria M. Richon, Stéphane Emiliani et al. Proceedings of the National Academy of Sciences
  7. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer (2005)
    William Kevin Kelly, Owen A. O’Connor et al. Journal of Clinical Oncology
  8. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease (2003)
    Emma Hockly, Victoria M. Richon et al. Proceedings of the National Academy of Sciences
  9. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. (2003)
    Wm. Kevin Kelly, Victoria M. Richon et al. PubMed
  10. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors (2004)
    Yufang Shao, Zhonghua Gao et al. Proceedings of the National Academy of Sciences

Immediate Impact

15 by Nobel laureates 20 from Science/Nature 79 standout
Sub-graph 1 of 22

Citing Papers

Human TKTL1 implies greater neurogenesis in frontal neocortex of modern humans than Neanderthals
2022 StandoutScienceNobel
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
2019 Standout
22 intermediate papers

Works of Paul A. Marks being referenced

Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies
2005
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
1999 StandoutNature
and 28 more

Author Peers

Author Last Decade Papers Cites
Paul A. Marks 17540 2000 1720 4521 2038 201 22.0k
Doriano Fabbro 12286 1188 2049 3705 2606 221 20.1k
Lorenzo A. Pinna 15777 813 1489 3341 1030 447 21.3k
Richard A. Rifkind 11335 1530 1035 2885 1255 123 14.2k
James A. McCubrey 15892 945 1537 6723 2610 419 24.5k
Nissim Hay 19923 2090 1020 4807 1050 159 27.4k
Alberto M. Martelli 12498 1238 1073 3396 2226 412 18.8k
Paul Dent 15450 899 1273 6946 1589 385 22.9k
Steven Grant 16595 713 1640 6192 3552 447 23.0k
Brett P. Monia 13731 1989 2041 3264 1770 272 21.5k
Bart Vanhaesebroeck 14367 1531 3403 4030 1326 192 22.2k

All Works

Loading papers...

Rankless by CCL
2026